A snapshot of upbeat PhII NASH data — from a very small trial — triggers a frenzy for Viking’s stock
Viking Therapeutics $VKTX has proven once again that nothing whips up biotech investors like positive Phase II numbers for NASH.
The San Diego-based biotech’s shares …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
